Sujet(s)
Trouble obsessionnel compulsif , Psoriasis , Humains , Trouble obsessionnel compulsif/épidémiologie , Trouble obsessionnel compulsif/diagnostic , Psoriasis/psychologie , Psoriasis/épidémiologie , Psoriasis/complications , Études cas-témoins , Femelle , Mâle , Adulte , Adulte d'âge moyen , États-Unis/épidémiologie , Jeune adulte , Adolescent , Sujet âgéRÉSUMÉ
Atopic dermatitis (AD) has been previously associated with migraine headaches in paediatric and adolescent populations, though there is less evidence for this relationship among adults. In this cross-sectional study, we investigated the association between AD and migraine among a cohort of US adults in the All of Us research programme. After controlling for common comorbidities, we found that adults with AD were 89% more likely to have a diagnosis of migraine (OR = 1·89, P < 0·001).
Sujet(s)
Eczéma atopique , Migraines , Santé de la population , Adolescent , Adulte , Humains , Enfant , Eczéma atopique/complications , Eczéma atopique/épidémiologie , Eczéma atopique/diagnostic , Études transversales , Comorbidité , Migraines/complications , Migraines/épidémiologie , Indice de gravité de la maladieRÉSUMÉ
Psoriasis is a common chronic inflammatory disease with multiple known comorbidities. Increasing evidence suggests some mechanistic overlap in the immunopathogenesis of psoriasis and some cases of asthma and allergic rhinitis (AR), but the potential association between psoriasis and asthma and AR has not been thoroughly investigated. The study aimed to investigate the association between psoriasis and asthma and AR. We used data from the NIH All of US Research Program, a nationwide longitudinal cohort of US adults, collected from 2018 to present. The source population comprised a demographically and socioeconomically diverse cohort of over 300,000 Americans. We used multivariable logistic regression models to examine the association between psoriasis and asthma and AR, after adjusting for sociodemographic variables, body mass index, and smoking status. In total, 235,551 participants (mean [SD] age, 54.7 [16.6] years; 59.3% female), including 5165 individuals with psoriasis and 230,386 individuals without psoriasis, were included in our analysis. Participants with psoriasis had significantly higher prevalence of asthma (26.1% vs. 12.9%; P < 0.001) and AR (31.8% vs. 13.4%; P < 0.001) compared to participants without psoriasis. Psoriasis was significantly associated with both asthma [adjusted odds ratio (aOR) 2.22; 95% confidence interval (CI) 2.08-2.37] and AR (aOR, 2.57; 95% CI 2.42-2.73). In subgroup analyses, associations remained stable in multivariable analyses after stratification by age, sex, and income. Psoriasis is associated with both asthma and AR in our sample of US adults. Further research is needed to explore potentially unifying inflammatory pathways among psoriasis, asthma, and AR.
Sujet(s)
Asthme , Santé de la population , Psoriasis , Rhinite allergique , Adulte , Humains , Femelle , Adulte d'âge moyen , Mâle , Études transversales , Rhinite allergique/épidémiologie , Rhinite allergique/complications , Asthme/épidémiologie , Psoriasis/épidémiologie , Psoriasis/complications , PrévalenceSujet(s)
Lichen scléroatrophique , Santé de la population , Psoriasis , Kraurosis vulvaire , Femelle , Humains , Lichen scléroatrophique/complications , Lichen scléroatrophique/épidémiologie , Études transversales , Kraurosis vulvaire/complications , Kraurosis vulvaire/épidémiologie , Psoriasis/complications , Psoriasis/épidémiologieRÉSUMÉ
Lichen planus (LP) can be accompanied by psychiatric comorbidities. Studies investigating the relationship between LP and clinically diagnosed anxiety and depression are limited. We aimed to determine the association of LP with anxiety and depression by conducting a cross-sectional population study of the All of Us research database, a National Institutes of Health cohort. Patients with LP were identified through electronic health record data using codes from the International Classification of Diseases and Systematized Nomenclature of Medicine. We used multivariable logistic regression to assess associations between LP and anxiety and depression before and after controlling for relevant covariates. Among 239,552 participants, 1083 individuals with LP were identified, with an average age of 67.20 years (standard deviation, 11.79) and a female predominance (74% female). The prevalence of depression and anxiety were higher among individuals with LP than in those without (41.6% vs 27.7%, p < 0.001; 43.5% vs 29.6%, p < 0.001). LP remained significantly associated with depression (OR, 1.36; 95% CI, 1.20-1.56, p < 0.001) and anxiety (OR, 1.48; 95% CI, 1.30-1.68, p < 0.001) after controlling for age, sex, hypothyroidism, autoimmune diseases, hypertension, type II diabetes mellitus, cardiovascular disease, and hepatitis C infection. In this cross-sectional study, LP was associated with an increase in odds of having depression and anxiety in multivariable analysis. Further study is needed to better understand the relationship between mental health outcomes and LP to address the needs of patients with LP more completely.
Sujet(s)
Diabète de type 2 , Lichen plan , Santé de la population , Humains , Femelle , Sujet âgé , Mâle , Études transversales , Dépression , AnxiétéRÉSUMÉ
Primary, acute Epstein-Barr virus (EBV) infection is associated with a variety of cutaneous eruptions, including the viral exanthem of infectious mononucleosis and erythema multiforme. Latent, chronic EBV infection can rarely result in development of lymphoproliferative disorders with cutaneous manifestations; however, these disorders do not arise from primary infection. In this report, we present a case of primary, acute EBV infection presenting with histopathologic features closely mimicking aggressive cytotoxic cutaneous T-cell lymphoma.
Sujet(s)
Infections à virus Epstein-Barr , Exanthème , Lymphome T cutané , Syndromes lymphoprolifératifs , Tumeurs cutanées , Humains , Infections à virus Epstein-Barr/anatomopathologie , Herpèsvirus humain de type 4 , Syndromes lymphoprolifératifs/anatomopathologie , Lymphome T cutané/diagnostic , Lymphome T cutané/complications , Tumeurs cutanées/diagnostic , Tumeurs cutanées/complicationsSujet(s)
Alcoolisme , Eczéma atopique , Santé de la population , Adulte , Humains , Eczéma atopique/épidémiologie , Études cas-témoins , Anxiété , DépressionRÉSUMÉ
Almost 1 billion people worldwide have acne, and oral tetracyclines, including doxycycline and minocycline, are effective and frequently prescribed treatments for acne. However, there is growing concern for the development of antibiotic resistance with such widespread utilization by dermatologists. Additionally, tetracyclines are known to have various potential side effects, including gut dysbiosis, gastrointestinal upset, photosensitivity, dizziness, and vertigo. However, in 2018 a novel narrow-spectrum tetracycline, sarecycline, was Food and Drug Administration-approved to treat moderate-to-severe acne vulgaris in patients 9-years-old and above. Sarecycline was designed to target Cutibacterium acnes, the pathogenic bacterium in acne vulgaris, which may reduce the risk of resistance. This paper examines the growing concerns of antibiotic resistance due to oral tetracycline usage in the treatment of acne vulgaris, with a focus on the promising third-generation, narrow-spectrum tetracycline, sarecycline.
RÉSUMÉ
Novel biologic therapies have revolutionized the treatment of psoriasis and atopic dermatitis. Although they are generally safe, they are immunomodulatory and therefore unique considerations apply in regards to infections and vaccine administration. This review aims to provide a clear and practical guide for dermatologists or other healthcare providers to reference when caring for psoriasis or atopic dermatitis patients being treated with biologic therapies using currently available guidelines and clinical data. Vaccinations for approved biologics including TNFα, IL-12/23, IL-23, IL-17, and IL-4/13 inhibitors will be discussed, with a special note on current COVID-19 vaccination recommendations.
Sujet(s)
COVID-19 , Eczéma atopique , Psoriasis , Biothérapie , Vaccins contre la COVID-19 , Eczéma atopique/traitement médicamenteux , Humains , Inhibiteurs des interleukines , Psoriasis/traitement médicamenteux , VaccinationSujet(s)
Trouble déficitaire de l'attention avec hyperactivité , Eczéma atopique , Adulte , Trouble déficitaire de l'attention avec hyperactivité/complications , Trouble déficitaire de l'attention avec hyperactivité/épidémiologie , Études cas-témoins , Comorbidité , Eczéma atopique/complications , Eczéma atopique/épidémiologie , Humains , Facteurs de risqueRÉSUMÉ
BACKGROUND: There is an incomplete understanding of the risk of COVID-19 infection in atopic dermatitis (AD) patients. OBJECTIVE: To evaluate the risk of COVID-19 infection in AD patients in a large, diverse cohort. METHODS: A case-control study of the All of Us cohort to analyze the association between AD and COVID-19. Comorbidities and risk factors were compared between cases and controls using multivariable analyses. RESULTS: In a cohort of 11,752 AD cases with 47,008 matched controls, AD patients were more likely to have a COVID-19 diagnosis (4.2% vs 2.8%, P < .001). AD remained significantly associated with COVID-19 in multivariable analysis (odds ratio, 1.29; P < .001) after adjusting for demographic factors and comorbidities. LIMITATIONS: Ascertainment of AD and COVID-19 cases using electronic health records and lack of clinical data on AD severity or therapy and COVID-19 outcomes. CONCLUSION: AD is associated with increased odds of COVID-19 infection even after controlling for common comorbidities.